The Neurodegeneration cluster portfolio consists of research on adult onset neurodegenerative diseases of all types, broadly focusing on pathogenesis, treatment and prevention. Research on the normal structure and function of neural systems is also included to enable identification of intervention strategies. The role of the programmatic team is to develop, implement and manage these research programs and to promote the translation of research findings into clinical practice. Included in the portfolio are topics such as neuronal cell death, protein misfolding, aggregation, and processing, mitochondrial pathologies, epidemiological studies, genetic studies including GWAS, biomarker studies, clinical studies including deep brain stimulation and gene therapy, and translational projects that will accelerate bench to bedside therapies for neurodegenerative disorders.
| Scientific Staff | Research Area |
| Beth-Anne Sieber, Ph.D. Program Director Point of contact: PD, ET, HSP, MSA, PSP |
Parkinson’s Disease (PD), Essential tremor (ET), Hereditary Spastic Paraplegia (HSA), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), orphan diseases, molecular biology, neurochemistry, cell biology, Deep Brain Stimulation, gene therapy, motor and non-motor manifestations, clinical trials |
| Margaret Sutherland, Ph.D. Program Director Point of contact: HD |
Huntington’s Disease (HD), Parkinson’s Disease, GWA studies, genetics, biomarkers, stem cells, protein dynamics, gene silencing, translational research, clinical trials |
| Vacant: Please contact Margaret Sutherland, Ph.D. Program Director |
Amyotrophic Lateral Sclerosis (ALS), Frontotemporal dementia (FTD) |
| Vacant: Please contact Beth-Anne Sieber, Ph.D. Program Director |
Alzheimer’s Disease (AD), Vascular Cognitive Impairment (VCI) |
| Ti Lin, Ph.D. Program Analyst |
|
| Alexander Runko, Ph.D. Program Analyst |
Neurodegeneration
Neuroscience Center
6001 Executive Blvd.
Rockville, MD 20892